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Abstract: The recent advances for the synthesis and application of different metallocenes for Medicinal 
Chemistry is reviewed. This manuscript presents the different metallocene scaffolds, with special 
emphasis on ferrocene derivatives, and their potential pharmaceutical application. Over the last years, 
the synthesis of new metallocene compounds and their biological and medicinal effects against some 
types of diseases (e.g. anti-tumoral, antibiotics, anti-viral) have been reported. From the medicinal point 
of view, the attractive properties of metallocene derivatives, such as their high stability, low toxicity and 
appealing redox behaviors are particularly relevant. This area has attracted many researchers as well as 
the pharmaceutical industry due to the promising results of some metallocenes, in particular ferrocene 
compounds, in breast cancer and malaria. 
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1. INTRODUCTION 
 The metallocene unit is composed of a transition metal 
and two cyclopentadienyl ligands coordinated in a sandwich 
structure, where the two cyclopentadienyl anions are on 
parallel planes with equal bond lengths and strengths [1]. 
Ferrocene was the first discovered metallocene and has been 
largely studied throughout the last decades by the peculiar 
electronic properties and ease of functionalization [2]. 
Ferrocene derivatives have been applied in materials science 
[3] including electroactive and aerospace materials [4], 
sensors [5] and organometallic catalysts for different organic 
transformations [6]. The high stability of ferrocene in 
aqueous and aerobic media, the large variety of several 
derivatives as well as its favorable electrochemical properties 
have made ferrocenyl compounds very attractive scaffolds 
for biological [7] and pharmaceutical applications [8].  
 Recent reports have shown that some ferrocene 
derivatives are active in vitro and in vivo against different 
diseases including cancer (anti-tumoral), malaria (anti-
malaria) and human immunodeficiency virus (anti-HIV) [9]. 
 Other metallocene derivatives [10] such as titanocene, 
vanadocene, ruthenocene and zirconocene also exhibit 
catalytic properties, although these metallocenes are rarely 
used industrially. 
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 According to the number of published reviews on the 
metallocene research topic [11, 12] we decided to focus this 
mini-review mainly on the reports from the last three years 
(from 2013), especially concerning ferrocene derivatives, for 
application in medicinal chemistry. 
2. METALLOCENES AS ANTI-TUMORAL  
 Organometallic compounds as anticancer drugs have 
played a central role in the pharmaceutical industry since the 
1970s. These consist mainly of platinum complexes [13], 
however many side effects such as nephrotoxicity and 
ineffectiveness against platinum-resistant tumors are severe 
disadvantages [14]. 
 Over the last years, metallocene-based compounds have 
stepped into the spotlight as the future in metal-based 
scaffolds for medicinal chemistry. In the particular case of 
ferrocene its physicochemical properties, such as lipophilicity, 
redox profile and stability in aqueous and aerobic media, are 
very desirable as far as drug development is concerned. 
Furthermore, the ferrocene moiety is readily recognizable by 
amino acids, proteins, DNA and carbohydrates overly 
expressed in cancer tissues, which therefore may account for 
the typically enhanced targeting and efficiency observed for 
such compounds [15]. 
 J.-P Monserrat et al. [16] reported the preparation and 
study of some ferrocene derivatives, such as ferrocenyl-
modified flavonoids with the purpose of improving the 
cytotoxic and vascular disrupting activities of flavonoids. A 
variety of ferrocenyl flavonoids were synthesized and tested 
for antiproliferative effects on B16 murine melanoma and 
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potential vascular disrupting effects on EAhy 926 endothelial 
cell models. The study showed that the cytotoxic and 
morphological activities of the compounds tested were not 
actually correlated. The presence of a ferrocenyl group in the 
flavones led to a clear increase in cytotoxic activity on 
cancer cells but no activity relationship regarding the 
morphological effects on endothelial cells was observed. 
Ideally, the most promising drugs would possess both 
cytotoxic and antivascular properties. Nevertheless, it is 
expected that these ferrocene flavones will act as pure 
antivascular agents in vivo, destroying tumor vasculature 
without directly interfering with cancer cell growth or division. 
 J. Mólnar et al. [17] conducted a cancer research in 
which flavonoids were shown to inhibit several pathways 
regarding drug resistance, apoptosis, division and metastasis 
as well as being an important class of vascular disrupting 
agents. These experiments suggested that a fast destruction 
of the tumor vasculature occurs, thus preventing oxygen and 
nutrient flow to the tumor. Canzhong Lu et al. [18] studied 
the combination of a ferrocene with an isoxazole compound 
in order to test the activity of various structures based on the 
isoxazole moiety containing ferrocene derivatives against 
some types of cancer cells. This isoxazole moiety is usually 
introduced into drug molecules to improve their biological 
activity and therefore the possibility to combine with 
ferrocene, one of the most attractive pharmacophores for 
drug design and discovery, has been reported with particular 
interest. Seven novel structures were synthesized and their in 
vitro anticancer activity against several cancer cell lines, 
namely MCF-7 (breast), A549 (lung) and HCT116 (colorectal) 
was evaluated using the MTT method. The results indicated 
that introducing the isoxazole moiety to the ferrocene core 
greatly improves its anticancer activity. The most promising 
candidate for the development of anticancer drugs was 
ferrocene carboxylic acid 3-(2-chloro-phenyl)-isoxazol-5-yl-
methyl ester (1), which showed IC50 values of 0.747 nM and 
3.65 nM for the A549 and HCT116 cell lines, respectively. 
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Scheme (1). 
 
 Various types of cancer are treated through photochemical 
methods, such as PhotoDynamic Therapy (PDT), a recent 
technique which uses porphyrin dyes and requires a 
photosensitizing drug, light and oxygen to initiate a photo 
chemical reaction that results in the generation of highly 
reactive singlet oxygen (1O2) species. The administration of 
the drug into the tumor site generates the reactive oxygen 
species upon photo-activation, damaging the tumor cells. 
However, the approved drugs for this therapy show severe 
side effects such as skin-photosensitivity and hepatotoxicity. 
The use of biocompatible transition-metal complexes could 
overcome these issues by using photosensitizers that are 
active in the PDT spectral window. B. Balaji et al. [19] took 
into account the high biological stability and non-toxicity 
with reversible redox properties of ferrocene to develop new 
ferrocene-conjugated oxovanadium (IV) complexes capable 
of indicating photo-induced DNA damage activity and 
photocytotoxicity, remaining non-toxic in the absence of 
light. The reported results showed that the oxovanadium  
(IV) complexes composed of ferrocenylmethylbis-(2-
pyridylmethylamine) linked to an acetylacetone unit 
presented the highest IC50 values in HeLa cells in the dark 
(IC50 > 100 µM) comparing to the other compounds studied 
and the second highest in visible light. Therefore, by having 
high photocytotoxic behavior, these complexes may be 
suitable for PDT applications.  
 There have been a novel series of asymmetric 
poly(amidoamine) (PAMAM) dendrons containing a single 
ferrocene unit prepared and tested for anti-cancer activity by 
real-time cell analysis and cell viability techniques. It was 
observed that while cell viability decreased, anti-cancer 
activity increased gradually in a dose-dependent manner in 
one, two, and three generations of the ferrocene-PAMAM 
dendrons. Dendrons have been extensively used in drug 
delivery systems due to their highly branched, three 
dimensional, and its monodisperse structure as well as a 
suitable method of synthesis. In this context, PAMAMs have 
been extensively studied in drug delivery due to the ability to 
control their size and shape, ease of functionalization, low 
toxicity, as well as high availability. T. Sağir et al. [20] 
verified that the ferrocene-cored PAMAM dendrons with 
several generations presented a definite structure-activity 
relationship. In general, the size of the dendron linked to the 
ferrocene unit directly correlates with the increase of water 
solubility of the compounds. Consequently, this increase in 
water solubility seems to enhance the cytotoxic and cell 
death apoptotic effects by apoptosis and necrosis in vitro, 
concluding that the ferrocene compounds with the larger 
dendrons would more likely be soluble in the body 
generating the active ferrocene drug species. 
 The delivery of bioactive drugs in pharmacology through 
nanotechnology has been known to be an innovative 
revolution by developing drug nanocarriers or drug delivery 
systems (DDS) that can boost the bioavailability of drugs. It 
is required that these drug nanocarriers of DDS are “smart” 
which have to be constructed with well-defined structures to 
include therapy drugs as well as to have the ability to release 
the loaded drugs in response to environmental stimuli under 
specific conditions. The construction of supramolecular 
vesicles from novel supramolecular amphiphiles through 
host-guest interactions, particularly with stimuli-responsiveness, 
is of great interest and importance in biotechnology and 
biomedicine, especially drug delivery. L. Wang et al. [21] 
reported a novel supramolecular amphiphilic inclusion 
between water soluble pillararene (WP6) and a hydrophobic 
ferrocene derivative, N-1-decyl-ferrocenylmethylamine, in 
aqueous solution, which was further applied to create 
nanoscale supramolecular vesicles with pH responsiveness 
for drug delivery. Pillararenes are a new class of macrocyclic 
hosts in supramolecular chemistry and ferrocene was found 
to strongly bind WP6 in water to achieve a stable amphiphilic 
inclusion complex and thus form supramolecular vesicles in 
water by self-assembly.  
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 The well-known electrochemical properties of ferrocene 
derivatives are also an added value in cancer therapy. L. 
Snegur et al. [22] studied redox-active ferrocene modified 
pyrimidines and adenine as potential antitumor agents. More 
precisely, several enantiopure ferrocenyl-(alkyl)pyrimidines 
and ferrocenyl(ethyl)adenine were tested for effects on the 
DNA synthesis in ovarian cancer cells. The results suggest 
that DNA may be one of the most probable primary cell 
targets for the ferrocene modified compounds exhibiting 
antitumor effects at low doses.  
 A. Badshah et al. [23] reported the cytotoxic effect 
against ovarian cancer cell lines of new ferrocene 
compounds incorporating N,N´-disubstituted thioureas. The 
observed results provided support to the idea that these 
compounds undergo electrostatic interactions with the 
anionic phosphate DNA backbone, thus suggesting that non-
covalent interactions may be appropriate to induce cell death.  
 One of the most important features concerning the 
development of new chemotherapy approaches is related 
with the mitigation and elimination of side effects. It is 
believed that their origin is due to the generation of the free 
radicals and the reactive oxidant species (ROS). Thus, the 
design of new and efficient chemotherapeutic drugs may 
reside on the combination of antioxidant and anticancer 
activities, by which the free radicals and ROS produced can 
be scavenged promptly thus limiting their action on healthy 
cells. Schiff-bases, particularly hydroxyl-substituted ones, 
have drawn significant attention due to their fine free radical 
scavenging and anticancer activities. Y.-N. Liu et al. [24] 
synthesized three new hydroxyl-substituted Schiff-bases 
containing ferrocenyl moieties and found that compound 2 
was a capable candidate to achieve the double function of 
antioxidant and anticancer activities in cancer chemotherapy, 
and offered an alternative to conventional chemotherapeutic 
agents or the co-administration of antioxidants and 
anticancer drugs. In vivo experiments are currently being 
conducted to assess the biological activities of the Schiff-
base compounds containing ferrocenyl moieties. 
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 Furthermore, new ferrocenyl compounds containing 
1,2,4-triazole units, as well as other known bioactive 
derivatives, have been recently investigated as anticancer 
agents against lung cancer, one of the most common 
malignant human tumors and a leading cause of death 
worldwide. Y. Li et al. [25] investigated the effects of 
various novel 1-ferrocenyl-2-(5-phenyl-1H-1,2,4-triazol-3-
ylthio) ethanone derivatives on human lung cancer cells in 
vitro and found that the compounds exerted anti-cancer 
effect G1-phase cell cycle arrest. Much attention has also 
been focused on pyrazoles which display diverse biological 
activities including anti-cancer and whose structures have 
been found among naturally occurring compounds such as 
the antibiotic pyrazofurin, documented to possess potent 
anti-cancer and antimicrobial activities. B. Zhao et al. [26] 
reported the synthesis of several ferrocene derivatives based 
on pyrazoles with optical activity showing that some of the 
compounds exerted notable cytotoxicity and selectivity for 
lung cancer cells. 
 Breast cancer (BC) is the most frequently diagnosed 
cancer in women around the world and accounts for about 
23% of the total cancer cases. [27] Surviving BC has been 
increasing since the early 1990´s thanks to important 
breakthroughs in medicinal therapies. Nevertheless, it still 
remains as the main cause of death from cancer among 
women, representing about 14% of global cancer deaths. The 
triple negative breast cancer (TNBC), defined by the absence 
of the estrogen receptor alpha (ERa), the progesterone 
receptor (PR) and the human epidermal growth factor 
receptor 2 (HER2), accounts for almost 20% of all breast 
cancer cases and is responsible for a high rate of mortality. 
TNBC usually occurs in younger women and denotes the 
most intense form associated with a high risk of 
reappearance, visceral and central nervous system metastases 
and early death. Tamoxifen has been the oldest and most 
prescribed drug against BC, however, over the years, its use 
for long periods of time led to the development of drug 
resistance phenomena. In this context, A.-L. Lainé et al. [28] 
divised a strategy of coupling ferrocene to hydroxytamoxifen 
(3) meant to supplement Tamoxifen with a redox entity in 
order to overcome the therapeutic limitation found with the 
organic analogue. The evaluation of this novel drug on a 
TNBC xenografted model confirmed that a marked delay in 
tumor growth was observed and consequently a significant 
decrease in tumor volume in comparison to the untreated 
group of mice was recorded. The results represented the first 
evidence of an in vivo effect of 3 and ferrocenyl derivatives 
in general on xenografted breast tumors. 
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Scheme (3). 
 
 Although it isn’t particularly active against breast cancer 
cells, the diphenylferrocenyl derivative 4 has already 
demonstrated to have a strong cytotoxic effect against SF-
295 human glioblastoma, HCT-8 human colon cancer, and 
HL-60 acute promyelocytic leukemia cell lines with IC50 
values below 2 µM. Its mechanism of biological action 
against HL-60 cells has been subsequently investigated by 
the group of E. A. Hillard. [29] Morphological analysis 
showed that the cell death was caused by apoptosis via 
intercalation of the DNA, as well as activation of caspases 3 
and 7 and externalization of phosphatydilserine. In addition, 
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4 interfered with the cell cycle, leading to accumulation of 
cells in the G0/G1 phase. 
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Scheme (4). 
 
 G. Jaouen, [30] reported on the hydroxylated ferrocenyl 
diethylstilbestrol derivatives 5-7 as cytotoxic agents for 
hormone-independent breast cancer cell line MDA-MB-231. 
These compounds showed to be very effective with IC50 
values of 0.14 to 0.36 µM which are lower than the ones 
reported for ferrocidiphenol (8). As already reported for the 
family of ferrocenophenols, the presence of only one 
hydroxyl group has a negative effect in the cytotoxic effect, 
as compound 9 is four times less effective than the 
dihydroxyl analogue 6. The substitution of the ethyl group in 
8 by a methyl (10) or an ethyl ester (11) group increases the 
IC50 values to 1.09 and 1.16 µM, respectively, as well as 
removing the central double bond as in compound 12 (IC50 = 
3.13 µM). 
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8 R1 = Et, R2 = 4-OH-Ph
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Scheme (5).  
 
 J. Cázeres-Marinero et al. [31] prepared a new series of 
compounds, following the previously reported ferrocifen 
derivatives 12 and 13. With the introduction of a hydroxyl 
group at the tamoxifen moiety of these structures, 14 and 15, 
the cytotoxicity towards the triple negative MDA-MB-231 
and hormone-dependent MCF-7 breast cancer cells 
decreased between 1.9 and 4.2-fold. The carboxylic acid 
analogue (16) also presented a similar behavior. The only 
exception was the derivative 12 against MCF-7, which IC50 
value lowered from 2.01 to 1.50 µM. 
 By varying the alkyl chain length (compounds 17-22) 
IC50 values on the low micromolar range were obtained. [32] 
Primary amides once again showed to be the most effective 
towards MDA-MB-231 cells, with comparable IC50 values of 
0.54 and 0.50 µM by 22 and 12, respectively. On the other 
hand, the succinimide 23 was the most active against MCF-7 
cells (IC50 = 1.06 µM) followed by compound 22 (IC50 = 
1.30 µM). 
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15 n = 6, R1 = NHOH, R2 = OH
16 n = 6, R1 = OH, R2 = OH
17 n = 4, R1 = OH, R2 = H
18 n = 4, R1 = NHOH, R2 = H
19 n = 4, R1 = NH2, R2 = H
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Scheme (6).  
 
 A small library of ferrocenylvinyl chromones was 
prepared by K. Kowalski and co-workers. [33] The 
compounds 24-26 (Scheme 7) presented cytotoxic and 
antiproliferative activity towards hepatocellular carcinoma 
(Hep G2), ER+ (MCF-7) breast adenocarcinoma and 
leukemic (CCRF-CEM) human cancer cell lines with IC50 
values ranging from 23.0-50.0 µM. Compound 25 has the 
broadest spectrum of activity and the lowest IC50/IG50 
values, and the introduction of the hexacarbonyl cobalt (II) 
moiety (26) reduced the activity. The mechanism of action 
relies on the production of ROS species that yields DNA 
scission and genotoxic effects, and ultimately induces 
apoptosis. Moreover, the cycle of the studied cancerous cells 
arrested in the G2/M phase, the same as for the currently 
used active principals docetaxel and doxorubicin. 
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 P. Stepnicka reported the ferrocene compounds 
containing Au-Cl moiety in their structure. [34] The 
compounds 27-32 were evaluated for their cytotoxic activity 
towards the A2780 and A2780R (cisplatin resistant) human 
ovarian cancer cell lines, to which all were found to be active 
in the low micromolar range.  
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27 R = CH2CO2Me
28 R = CH2CONH2
29 R = CH2CH2OH
30 R = CH(CH2OH)2
31 R = C(CH2OH)3
32 R = CH2SO3(HNEt3)  
 
Scheme (8). 
 
 Compounds 27 and 29 were the most efficient with IC50 
values of 0.27 and 0.60 µM for A2780 and 3.10 and 6.50 µM 
for A2780R, respectively. Comparing to Cisplatin and 
Auranofin, both these compounds are more efficient against 
the first type of cells, while Auranofin is at least twice more 
cytotoxic for the second type of cells. Despite the promising 
antiproliferative results, these compounds lack cell 
selectivity as healthy HEK cells were also affected, with 
IC50(HEK/A2780) ranging from 1.6 (32) up till 5 (28). 
 Ligand 33 and its complexes with Co (II), Ni (II), Cu (II) 
and Zn (II) (34-37) were investigated as cytotoxic agents 
against cervical carcinoma (KB), ovarian carcinoma (SKOV-3), 
CNS cancer (SF-268), non-small lung cancer (NCl H460), 
colon adenocarcinoma (RKOP 27), leukemia (HL60, U937, 
K562), melanoma (G361,SKMEL-28), neuroblastoma (GOTO, 
NB-1), cervical cancer (HeLa), breast cancer (MCF-7), lung 
fibrosarcoma (HT1080) and hepatocellular liver carcinoma 
(HepG2) cells [35]. 
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Scheme (9). 
 
 All complexes performed better than the ligand itself, 
probably due to the enhanced lipophilic character of 
complexes vs the ligands, and the Zn-complex showed the 
best IC50 values with all cell lines. The ligand and the 
complexes exhibited IC50 values in the nano- and sub-
nanomolar range, and they were ubiquitously more effective 
on all cell lines comparing to current standard drugs for such 
cancer cells, except in the cases of KB, GOTO and NB-1 
cells. Further studies will be performed by the authors in 
order to assess the viability of these complexes as future 
anticancer drugs. 
 The ferronucleosides 38 and 39 containing a chiral 
hydroxylalkyl group were prepared and studied as cytotoxic 
and antiproliferative agents against murine leukemia 
(L1210), HeLa and human T-lymphocyte (CEM) cell lines. 
[36] Both compounds performed better than the derivatives 
40-43, showing that both nucleoside and hydroxyalkyl 
moieties are essential to the cytotoxic effects. All compounds 
showed IC50 values in the micromolar ou submicromolar 
range, with 38 being more effective towards L1210 cells and 
39 for CEM and HeLa, with IC50 values of 0.78, 0.35 and 
1.1, respectively. In general, compounds 38 and 39 
performed with comparable performance to cisplatin and 5-
fluorouracil. No evidences were observed for toxicity 
towards non-cancerous cells (IC50 > 50 µM). Moreover, 
compounds 38 and 39 are non-mutagenic, in addition to an 
antineoplasic activity comparable to 5-fluorouracil. 
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Scheme (10). 
 
 Six simple ferrocene phenyl ester derivatives substituted 
at para-position with halogen or pyrrolyl moieties (44-49) 
were prepared and tested against estrogen dependent MCF-7 
breast cancer cell lines and MCF-10A normal breast cell 
lines [37].  
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44 R = H      45 R = 1H-pyrrol-1-yl
46 R = F       47 R = Cl
48 R = Br     49 R = I  
 
Scheme (11). 
 
 While 4-(1H-pyrrol-1-yl)phenyl ferrocenecarboxylate 
(45) gave the lowest IC50 value for MCF-7 lines (1.4 µM), it 
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also had a strong toxic effect over the normal breast cells 
(IC50 of 1.8 µM). Despite the IC50 values of 9.2 and 33 µM, 
the p-bromophenyl ferrocenecarboxylate (48) showed the 
highest IC50 (MCF-10A/MCF-7) ratio of 38, followed by the 
chloro derivative 47, with 15, respectively. No cytotoxic 
effect was detected for the fluoro-compound 46, and the 
iodo- derivative (49) was far more toxic to normal cells than 
to the cancerous ones. Docking and electrochemical studies 
revealed that the high selectivity of the bromo- compound is 
not ascribed to anti-estrogenic properties but to the 
appropriate combination of the ferrocene moiety and the 
electronegativity and charge distributions. [37] 
 The quinolone-ferrocene hybrids 50-53 exhibited potent 
cytostatic effect, with GI50 values from 0.6-3.3 µM, as well 
good cytotoxicity, with LC50 values between 6-8 µM, against 
renal (TK10), melanoma (UACC62) and breast (MCF7) 
cancer cell lines. [38] Hybrids 52 and 53 exhibited the most 
potent cytostatic and cytotoxic effects on the proliferation of 
all three cancer cell lines, with LC50 and GI50 values ranging 
from 7.4 to 7.7 µM and 1.7 to 2.6 µM, respectively. Their 
mechanism of action may rely on the disruption of DNA 
transcription in the cancerous cells due to a possible optimal 
interaction with the negatively charged phosphate groups of 
the DNA backbone given by the three carbon atom spacing 
between two consecutive nitrogen atoms in the spacer of the 
hybrids. While compounds 50 and 51 showed to be the most 
antiproliferative of all, their high levels of toxicity towards 
Chinese Hamster Ovarian (CHO) cells (1.30 uM < IC50 < 
2.25 µM) makes them unwanted candidates for future 
studies. 
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Scheme (12). 
 
 The ferrocenylthiosemicarbazones 54-63 were prepared 
by Cortez-Maya et al. [39] and screened as cytotoxic agents 
towards human glyoblastoma U251, human prostatic 
adenocarcinoma PC-3, human chronic myelogenous 
leukemia K562, human colorectal adenocarcinoma HCT-15, 
human mammary adenocarcinoma MCF-7 and human lung 
adenocarcinoma SKLU-1 cell lines. 
 The compounds 58-63 inhibit the proliferation of all cell 
lines, with the meta- and para-chloro-derivatives 59 and 60 
showing the lower IC50 values, ranging from 0.34 mM for 59 
and MCF-7 cells to 22.3 mM for 60 and SKLU-1 cells. [39] 
These data for compound 59 are better than the ones 
recorded for cisplatin and, in addition, compound 59 did not 
show any activity against normal fibroblast NIH3T3 cells. 
Fe
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56 R = Pr            57 R = Bn
58 R = 2-Cl-Ph   59 R = 3-Cl-Ph
60 R = 4-Cl-Ph   61 R = 2-F-Ph
62 R = 3-F-Ph    63 R = 4-F-Ph
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Scheme (13). 
 
 A follow-up study on the cycloplatinated complex 64, 
previously prepared by M. Cascante [40,41], showed that it 
induces a phosphorylation of the tumor suppressor FOXO3a, 
leading to its the nuclear translocation and inhibition of 
upstream AKT phosphorylation. The cytotoxic activity in 
A549 cells is caused by the activation of intrinsic caspase 
pathway that leads to apoptosis. Moreover, it has low 
toxicity to healthy cells and it has a synergistic effect with 
cisplatin on A549 non-small lung cancer cell lines. 
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 The ferrocenyl-terpyridine oxovanadium (IV) complexes 
of curcuminoids 65-67 showed remarkable PDT activity in 
HeLa cells with IC50 dark/light ratios of 13-25.[42] In 
addition, they presented 5 to 10-fold selectivity towards the 
cancer cells over normal 3T3 cells due to the formation of 
hydroxyl radicals under blue or red light excitation. The best 
results were obtained for compound 65, showing the 
essential role of the methoxyl and hydroxyl groups of the 
curcumin moiety. Its photo-induced efficiency is indeed 
better than Photofrin®. The high cell uptake of 65 leads to its 
accumulation both in the cytosol and nucleus of the HeLa 
cells, and there are evidences that the cell death occurs via an 
apoptopic pathway. 
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Scheme (15). 
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 The ferrocenyl-L-amino acid copper(II) complexes 68-73 
(Scheme 15) by A. R. Chakravarty et al. [43] showed 
notable photocytotoxicity in HeLa and MCF-7 cancer cells 
with low dark toxicity (5.5 < IC50(dark/light) < 13.2), mainly 
because of the redox inactive copper(II) center. Both types of 
cells were mostly affected by compound 73, with IC50 values 
of 2.3 and 3.2 µM, respectively, under visible light. The 
compounds were mainly localized in the endoplasmatic 
reticulum of the HeLa cells, which, once the compounds can 
bind to DNA, can avoid the occurrence of mutations on 
nuclear DNA upon photoactivation. 
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 P. Kenny and co-workers [44] reported on the 1-alkyl-1’-
N-meta- and 1-alkyl-1’-N-para-(ferrocenyl)benzoyl dipeptide 
esters 74-79 that, from a wide family of 23 compounds, 
showed micromolar activity against the H1299 NSCLC cell 
line, with IC50 values in the range 2.6-20.1 µM. The best 
result was observed for compound 74, however cisplatin 
shows a lower IC50 value of 1.5 µM. Linking the ferrocene 
moiety at the ortho position of benzoyl group decreases the 
activity of the compounds. In addition, the cytotoxicity of 
the derivatives increases with a decrease of the size of the 
alkyl group on the previously reported unsubstituted 
cyclopentadiene ring. However, better results have 
previously been obtained without any alkylation of the 
cyclopentadiene ring in the orto- and meta- families of 
compounds, but in the para- positions this strategy enhanced 
the cytotoxic activity of the compounds. 
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Scheme (17). 
 
 G.S. Smith [45] performed preliminary in vitro 
proliferation studies of the ferrocenyl-derived ligands (80-
91) and the corresponding p-cymene-Ru(II) complexes 
([84][PF6]4-[87][PF6]8, [90][PF6], and [91][PF6]) towards five 
distinct cancer cell lines: A2780 and A2780cisR human 
ovarian, the SISO human cervix, the LCLC-103H human 
lung, and the 5637 human bladder. In general, these 
compounds showed to be very specific for ovarian cancer 
cells, with nine of them inhibiting the growth of both the 
A2780 and A2780cisR cell lines in more than 50% at a 
concentration of 5 µM. Quite strong antiproliferative effects 
were also observed for the 5637 bladder cancer line, while 
both the SISO and LCLC-103H lines were generally more 
resistant.  
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Scheme (18).  
 
 The first- and second-generation ferrocenyl-derived N,O-
p-cymene-ruthenium-PTA metallodendrimers have shown to 
be the most active of the series. Further studies will be 
carried on by the authors, considering that adequate chemical 
transformations will have to be made taking into account the 
poor solubility of the compounds in the testing media. 
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 The simple fluorescent Pt complex 92, prepared by R. 
Yousefi and co-workers [46], showed very strong 
antiproliferative effect on human T-cell lymphoblast Jurkat 
cell line, and, to a smaller extent, also on human breast 
adenocarcinoma MCF-7 cell line. After 24 and 48h of 
incubation 92 showed lower IC50 values than the standard 
cisplatin, more precisely 1.46 and 0.46 µM for the former, 
and 18.21 and 8.71 M for the latter. The complex actuates 
through a mixed-binding mode, comprising partial 
intercalation, electrostatic binding and coordination to 
hsDNA that ultimately leads to apoptosis. 
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Scheme (19). 
 
 The dichlorido(ethane-1,2-diamine)platinum(IV) complexes 
93-95 and oxaliplatin derivatives 96-100 were found to be 
very cytotoxic towards cisplatin-sensitive ovarian carcinoma 
CH1 cell lines, with IC50 values ranging from 0.84–2.3 µM 
with no particular distinction between the two kinds of 
compounds. [47] On another hand, the oxaliplatin 
derivatives 96-100 showed to be far more cytotoxic towards 
the intrinsically cisplatin-resistant SW480 colon carcinoma 
cell lines than the cisplatin-like complexes 93-95, with IC50 
values ranging from 2.7-5.6 µM and 32-46 µM, respectively. 
Finally, low to moderate cytotoxic effect was addressed to 
non-small cell lung carcinoma A549 cancer cells by both 
types of complexes (IC50 > 24 µM). However, none of the 
studied complexes outperformed oxaliplatin in any of the 
cancer cell lines. Overall, no particular relation between the 
cytotoxic effect and the chain lengths or the linking 
fragments can be established. 
 The hetero-bimetallacycles containing Pd (II) and Pt (II) 
104 and 105, respectively, were found to be more efficient 
than cisplatin against T98G brain cancer, KB head and neck 
cancer and SNU80 thyroid cancer cells, as well as less toxic 
to normal human HEK-293 cells at effective concentrations 
between 0.5 and 16 µM. [48] As expected, the complexes 
also were also more cytotoxic than the monomers 101-103. 
The IC50 values ranged from 4.5-12.0 µM and 5.2-18.3 µM 
for 105 and 104, respectively, for the cancerous cells, with 
particular selectivity for the T98G cells. The cellular uptake 
of 105 in these cells is also more efficient than 104’s, and its 
genotoxicity promotes oxidative stress that ultimately leads 
to cell death probably by an apoptotic pathway. 
 The carbohydrate Pd (II) complex 106 bearing a 
ferrocenyl ester moiety prepared by R. Trivedi and co-
workers [49] was studied as cytotoxic agents against A549, 
HeLa, MDA-MB-231 and MCF-7 cell lines. However, it 
only presented activity towards the first cell line with an IC50 
value of 13.18 µM, which was higher than the 5.73 µM 
found for its less bulky precursor 107 (5.73 µM), as well as 
doxorubicin (0.46 µM) and cisplatin (0.15 µM). 
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 The (4-ferrocenylphenyl)propargyl ether derived 
carbohydrate triazoles 108-114 were tested as cytotoxic 
agents against HeLa, MDA-MB-231 and MCF-7 cell lines. 
[50] Only 113 and 114 showed activity, with moderate (9.0 
µM) to high (61.79 µM) IC50 values being obtained. The 
reason for the poor performance of these compounds may lie 
on the hydrophobic character of the phenoxymethyl triazole 
moiety, as previously prepared amide-triazole derivatives 
demonstrated much higher activity. 
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 The introduction of a ferrocene moiety in the structure of 
the natural compound plumbagin (115) enhanced its inherent 
cytotoxic activity towards cells of human 518A2 melanoma, 
HCT-116 colon carcinoma and also the multi-drug resistant 
KB-V1/Vbl cervix carcinoma, with IC50 values of 0.5, 4.7 
and 1.1 µM versus 1.1, 5.8 and 26.2 µM, for the derivative 
and parent compounds, respectively. 
 In addition, the growth of chicken heart fibroblasts was 
not affected by 115, showing a good selectivity towards 
cancer cells [51]. The cell cycle stopped at the G1-S phase in 
the presence of the ferrocenyl derivative, and significant 
dose and time-dependent increases of dying cancer cells 
(sub-G0/G1 fraction) were observed after treatment. In 
agreement, 115 precipitated a more extensive change of the 
shape of linear DNA probably due to the intercalation of the 
naphthoquinone unit bearing a large orthogonal metal 
complex fragment running alongside the DNA or/and of 
additional ROS-induced lesions. Finally, the authors 
correlate the high efficacy of 115 against the multi-drug 
resistant KB-V1/Vbl cervix carcinoma with the inhibition of 
the drug efflux Pgp-type pumps which are overexpressed in 
this particular cell line. A similar synthetic approach was 
conducted with the natural analogue Juglone, which is 
particularly effective against the human 518A2 melanoma 
and HCT-116 colon carcinoma cell lines. However, the 
inherent cytotoxic effect was lost with the introduction of the 
ferrocenyl moiety-containing 116, showing the detrimental 
effect that simple and small chemical groups can have on the 
biological activity of compounds. 
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 The natural compound egonol has also been 
functionalized with several ferrocene moieties, yielding 
compounds 117-120 [52].  
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 These compounds were tested as cytotoxic agents  
for wild-type CCRF-CEM and multidrug-resistant P-
glycoprotein-over-expressing CEM/ADR5000 human 
leukemia cells, with 117 showing very strong selectivity 
towards the first cell line, given by the IC50 values of 0.07 
and 147.27 µM, respectively. In another hand, compound 
119, which encompasses the anti-malaria active 1,2,4-
trioxane moiety linked to ferrocene by an ester group, has a 
very strong effect in both types of cells with IC50 values of 
0.25 and 0.57 µM, respectively. Finally, the dimeric egonol-
ferrocene aggregate 118 and its monomer 120 were only 
active towards CCFR-CEM cells, with IC50 values of 3.17 
and 36.15 µM. Despite lower than doxorubicin for the first 
cell line, the high efficiency of compounds 117 and 119 may 
actually be related to the cooperative and synergistic effect 
of the endoperoxide bridge and the ferrocene unit, given the 
lower activity observed for analogous compounds without 
these units. 
 The ferrocenyl derivatives of the natural compounds 
pterocarpene and coumestan, and other chromones 121-126 
were screened as cytotoxic agents against MCF-7 and MDA-
MB-231 mammary carcinoma cells and HT-29 colon 
carcinoma cells. [53] Compounds 123 and 126 did not 
present any cytotoxic activity towards the studied cell lines. 
The lower IC50 values were recorded for compounds 124 and 
125, which were active against all cell lines. However a 
higher toxicity towards human RC-124 epithelial kidney 
cells than for the cancerous ones was observed. Both 
complexes 121 and 122 were more selective towards the 
HT29 cancer cells, with IC50 values of 30 µM, than the 
healthy ones. Compound 122 was also effective against 
MCF-7 cells showing an IC50 value of 46.3 µM. 
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2.1. Mechanistic Studies 
 C. Amatore and co-workers [54] reported that the 
previously prepared ferrocifen derivatives 3, 8 and 127 
actuate by distinct mechanistic pathways. In general, their 
mechanism of action relies on the formation of a quinone 
methide derivative upon oxidation of the ferrocene moiety, 
which is not attainable by 127 due to structural features. 
Moreover, despite their similar structures, ROS/RNS 
production in a stressful environment is enhanced by the last 
two compounds in opposition to the former. 
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2.2. Other Organometallic Complexes 
 Several other organometallic complexes containing Au 
[55,56], Rh [57], Ru [58, 59], Ir [60], Ti [61, 62] and Os [63] 
in their structure have also been reported to exhibit 
interesting anti-cancer activities. 
3. METALLOCENES AS ANTI-MALARIA  
 The parasite disease malaria still remains the most 
common among tropical regions and affects more than 200 
million people, lethal in 627.000 cases in 2013. [64,65] The 
most dangerous of the five single cell protozoan parasites of 
the Plasmodium species is the P. falciparum, accounting for 
about 90% of all deaths from malaria. [66] The quinoline-
based compound, Chloroquine (128) has been known to have 
lost its efficacy, encountering chemo-resistance issues, 
creating the urgent need to discover novel anti-malarial 
agents. The fact that using metal complexes enhances the 
biological activity of compounds has evolved into an 
important research strategy in biological communities as 
well as in organometallic chemistry. The ferrocene-based 
drug ferroquine (129) has been the most successful example 
of a new antimalarial which is highly active against 
chloroquine-resistant strains, currently developed by Sanofi-
Aventis [67]. 
 Plasmodium vivax is responsible for about half of the 
malaria cases located in south-east Asia and in the Pacific 
coast. An in vitro evaluation of the efficacy of 129 versus 
other reference anti-malaria agents on blood isolates infected 
with P. Vivax was thoroughly conducted through the 
invention of Fraisse& Struxiano [68] on the use of 129 or its 
N-demethylated metabolite compound 130 in the treatment 
and/or prevention of malaria. This invention demonstrated 
that compound 129 was always active throughout the various 
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parasite growth stages, whereas 128 proved to be 10 to 20 
times less active in mature stages. Furthermore, due to its 
promising results, a unit form of administration of 129 in 
tablet form was suggested. 
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 Through the work of A. Patti et al. [69] other 
ferrocenylquinolines have also been synthesized and 
prepared as a potentially useful class of bioactive 
organometallics and evaluated against malaria. A new class 
of substituted quinolines bearing a ferrocene unit connected 
to the heterocycle in the side chain has been screened for 
their activity in the growth inhibition of chloroquine-
susceptible D10 and chloroquine resistant W2 strains of P. 
falciparum using chloroquine as reference drug. Although 
the obtained products were found not active against the 
parasite, the authors acknowledged the given contributions 
of the ferrocenyl and dimethylamino substituents used. 
 J. Quirante et al. [67] reported other antimalarial 
ferrocene based compounds containing indole moieties. 
Indole molecules themselves have been extensively studied 
and proven to be attractive as lead compounds due to their 
low cost and straightforward synthesis. From the several 
ferrocene-indole hybrids prepared, compound 131 showed to 
be the most active one against P. Facliparium. 
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4. METALLOCENES AS ANTI-HIV AGENTS 
 C. Pereira et al. [70] conducted one of the many studies 
regarding the applications of ferrocene in medical research 
consisting on the preparation of some adducts through the 
incorporation of the ferrocenemethyl moiety into a 
heterocyclic base. This attracted some attention to the 
evaluation of these compounds against the human 
immunodeficiency virus (HIV) as well as other viruses such 
as hepatitis B (HBV) and bovine viral diarrhea virus 
(BVDV). M. Fouda et al. [71] observed that only compounds 
bearing thymine showed significant cytotoxicity against MT-
4 cells. It was shown that the ferrocenyl derivatives of 3’-
deoxy-3’-azidothymidine were active against HIV-1. 
However, they proved to less potent than 3’-α-
azidothymidine(AZT) used as the reference drug. 
 Other applications regarding the use of ferrocene 
derivatives against the activity of HIV are related to 
electrochemical examination of HIV enzymes using 
ferrocene-conjugated peptides. The main idea was to test the 
possibility of developing inhibitors that target different steps 
in the HIV life cycle by blocking the function of HIV-related 
proteins such as HIV-1 integrase (HIV-1 IN), HIV-1 reverse 
transcriptase (HIV-1 RT) and HIV-1 protease (HIV-1 PR). 
These are vital proteins that control the HIV’s ability to 
infect cells as well as the production of new copies of the 
virus.  
 H. Kraatz et al. [72] demonstrated for the first time the 
detection of these enzymes at a nanomolar level using 
ferrocene (Fc)-conjugated peptides on gold microelectrodes. 
The interaction between the Fc-conjugated peptides and the 
enzymes was studied through cyclic voltammetry. It was 
shown that the electrochemical behaviour of the surface-
bound Fc- bioconjugate changed as the protein concentration 
increased, suggesting that the HIV protein was binding to the 
peptide film and encapsulating the Fc redox center on its 
surface. 
5. CONCLUSION 
 Application of metallocenes especially ferrocene 
derivatives in medicine and pharmaceutical fields is a very 
attractive research area.  
 The high potential of some ferrocenyl derivatives for 
cancer therapeutics is well known in academia as significant 
in vitro cytotoxicity against several tumor cell lines, 
including prostate, lung, colon, leukemia and breast cancer 
cell lines, has been recorded in many cases. 
 Recent studies reported the importance of attaching 
specific units to ferrocene scaffolds for medicinal applications.  
 The use of metallocene derivatives especially ferrocene 
scaffolds (ferrocifens, ferrocenium and ferricenium salts and 
ferrocenyl complexes) as anti-tumoral, anti-malaria and anti-
HIV agents is very promising both in the academic and 
industrial points of view.  
 Combination of the redox properties of ferrocene and its 
high stability have also been explored in order to prepare 
electrochemical sensors for very different substrates such as 
DNA, proteins and environmental pollutants.  
 It would be of great interest to pursue the design of novel 
metallocene derivatives which can improve water solubility 
and blood circulation life-time of standard drugs, and 
enhance selectivity towards cancer tissues. In parallel, the 
use of multifunctional drug delivery carriers would allow the 
potential combination between metallocene compounds and 
imaging agents and/or other drugs, opening future 
perspectives to enlarge the application of such compounds in 
theranostics. 
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